Volume 25, Number 9—September 2019
Research
Genetic Characterization and Enhanced Surveillance of Ceftriaxone-Resistant Neisseria gonorrhoeae Strain, Alberta, Canada, 2018
, Walter Demczuk, Jennifer Gratrix, Kanti Pabbaraju, Petra Smyczek, and Irene Martin
Table 2
Test results and antimicrobial resistance pattern predictions of sequence types identified from enhanced surveillance of Neisseria gonorrhoeae samples, Alberta, Canada*
| Sequence type by NG-MAST | No. specimens (% of all specimens), n = 232† | No. cases, n = 194† | Antimicrobial resistance pattern prediction‡ | No. specimens with specified AMR/no. cultures identified with ST§ |
|---|---|---|---|---|
| Nontypeable | 59 (25.4) | 35 | NA | |
| ST8890 | 34 (14.7) | 33 | TetR | 43/45 |
| ST5441 | 17 (7.3) | 17 | Susceptible | 66/79 |
| ST16065 | 12 (5.2) | 9 | CipR/TetR | 63/63 |
| ST14788 | 7 (3.0) | 6 | Susceptible | 21/26 |
| ST5985 | 7 (3.0) | 7 | TRNG | 649/730 |
| ST11086 | 6 (2.6) | 5 | CipR/EryR/PenR/TetR | 30/30 |
| ST12302 | 6 (2.6) | 6 | CipR/EryR/TetR/often AziR | 1,198/1,211 (CipR/EryR/TetR); 687/1,211 (are also AziR) |
| ST4637 | 6 (2.6) | 5 | Susceptible | 17/20 |
| ST8288 | 6 (2.6) | 6 | Penicillinase-producing/CipR | 12/14 |
| ST1387§ | 4 (1.7) | 4 | No culture available | 0 |
| ST16288 | 4 (1.7) | 4 | CipR/EryR | 26/26 |
| ST16972 | 4 (1.7) | 4 | Susceptible | 4/5 |
| ST17029 | 4 (1.7) | 4 | No culture available | 0 |
| ST18135 | 4 (1.7) | 2 | No culture available | 0 |
| ST4186 | 4 (1.7) | 4 | Susceptible | 4/4 |
| ST11461 | 3 (1.3) | 3 | TRNG | 161/166 |
| ST13489 | 3 (1.3) | 3 | Susceptible | 1/1 |
| ST16211 | 3 (1.3) | 2 | EryR/TetR | 2/2 |
| ST14698 | 2 (0.86) | 2 | AziR/CipR/EryR/TetR | 142/208 |
| ST16825§ | 2 (0.86) | 1 | No culture available | 0 |
| ST18126§ | 2 (0.86) | 2 | No culture available | 0 |
| ST18154 | 2 (0.86) | 2 | No culture available | 0 |
*N. gonorrhoeae infection was diagnosed by the Aptima Combo 2 nucleic acid amplification test kit (Hologic Inc., https://www.hologic.com). AziR, azithromycin resistant; CipR, ciprofloxacin resistant; EryR, erythromycin resistant; NG-MAST, N. gonorrhoeae multiantigen sequence typing; ST, sequence type; TetR, tetracycline-resistant; TRNG, TetR N. gonorrhoeae (high-level plasmid mediated).
†Sequence types detected in only 1 specimen and resistance patterns (if known) are as follows and represent individual cases unless noted as an additional site: ST10451 (PenR/CipR/EryR/TetR); ST11691 (CipR/EryR/TetR and half are AziR); ST11933 (susceptible or TetR); ST-16161 (TetR); ST16595 (TRNG); ST18146; ST18156; ST3935 (EryR/TetR, sometimes PenR); ST9120. Sequence types detected in only 1 specimen that had not previously been detected in Alberta are ST14797; ST17196; ST18057; ST18134; ST18136; ST18137; ST18138; ST18155 (additional site); ST18157; ST18158; ST18159; ST18160; ST18161; ST18162; ST18340 (additional site); ST18341; ST18342; ST18343; ST18344; ST18345 (additional site); ST5308 (XDR: AzR/CeDS/CipR/PenR/TetR/EryR); ST6339.
‡Based on data from the Canadian national gonococcal collection, which included 7,498 gonococcal cultures with sequence typing and phenotypic susceptibility results collected 2016–2018.
§Sequence type had not been previously detected in Alberta.